Frequently Asked Questions

 

Dexcom G6 Continuous Glucose Monitoring (CGM) System

How do patients remove their sensors?
Is Dexcom G6 indicated for paediatrics use?
How do patients help keep their sensors on for the full 10-day wear?  

Dexcom CLARITY  

How does a clinic get started with Dexcom CLARITY?  
What are the computer and internet requirements for Dexcom CLARITY?  
How do patients share data with my clinic?  
How do I save or print reports? 
Can I export raw data? 
What reports can I view in Dexcom CLARITY?
How do I view patient data? 
How do I know when Dexcom CLARITY has been updated?
Who do I contact with questions about Dexcom CLARITY?
Why do I need to change my clinic user password?
Is patient data shown in real-time or is it delayed?

 

Accessing CGM for my patients

Is there subsidy funding available for Dexcom CGM?
Which patients can benefit from Dexcom G6?
Can Dexcom G6 still be purchased privately?

General Enquiries & Support

If my patient needs assistance, who should they contact?
If I need assistance, who should I contact?
Where can I access more training and resources?

NEED HELP

Can’t find the answer to your question? Contact us, we are always ready to assist you with any questions you may have. 

 

References 

1 Chase HP, Messer L: Understanding Insulin Pumps and Continuous Glucose Monitors. 3rd ed. Denver: Children’s Diabetes Research Foundation, 2016. 

2 McNichol L, Lund C, Rosen T, Gray M: Medical adhesives and patient safety: State of the science: consensus statements for the assessment, prevention, and treatment of adhesive related skin injuries. J Wound Ostomy Continence Nurs 2013;40:365–380; quiz E361–E362. 

3 Englert K, Ruedy K, Coffey J, et al.: Skin and adhesive issues with continuous glucose monitors: a sticky situation. J Diabetes Sci Technol 2014;8:745–751. 

4 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371–378. doi:10.1001/jama.2016.19975

5 Šoupal J, Petruželková L, Flekač M, Pelcl T, Matoulek M, Daňková M, Škrha J, Svačina Š, Prázný M. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016 Sep;18(9):532-8. doi: 10.1089/dia.2016.0171. Epub 2016 Aug 2. PMID: 27482825; PMCID: PMC5035377.

6 Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, Hermanns N. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018 Apr 7;391(10128):1367-1377. doi: 10.1016/S0140-6736(18)30297-6. Epub 2018 Feb 16. PMID: 29459019.

7 Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2018 Apr;35(4):483-490. doi: 10.1111/dme.13561. Epub 2017 Dec 29. PMID: 29230878; PMCID: PMC5888121.

8 Grunberger G, Sherr J, Allende M, Blevins T, Bode B, Handelsman Y, Hellman R, Lajara R, Roberts VL, Rodbard D, Stec C, Unger J. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract. 2021 Jun;27(6):505-537. doi: 10.1016/j.eprac.2021.04.008. PMID: 34116789.